Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers. The editor-in-chief is Ruiwen Zhang (UH Drug Discovery Institute). The journal covers research on contemporary molecular drug targets involved in cancer, including medicinal chemistry, pharmacology, molecular biology, genomics, and biochemistry. Current Cancer Drug Targets publishes original research reports, review papers, and rapid communications ("letters").[1]
| Discipline | Oncology |
|---|---|
| Language | English |
| Edited by | Ruiwen Zhang |
| Publication details | |
| History | 2001–present |
| Publisher | |
| Frequency | 11/year |
| 2.912 (2019) | |
| Standard abbreviations | |
| ISO 4 | Curr. Cancer Drug Targets |
| Indexing | |
| CODEN | CCDTB9 |
| ISSN | 1568-0096 (print) 1873-5576 (web) |
| OCLC no. | 48132748 |
| Links | |
Abstracting and indexing
editCurrent Cancer Drug Targets is abstracted and indexed in:[2]
According to the Journal Citation Reports, the journal has a 2019 impact factor of 2.912.[3]
References
edit- ^ "Journal overview". Current Cancer Drug Targets. Bentham Science Publishers. June 2021. Retrieved 2021-06-14.
- ^ "List of indexing services". Current Cancer Drug Targets. Bentham Science Publishers. June 2021. Archived from the original on 2011-08-01. Retrieved 2011-08-04.
- ^ "Journals Ranked by Impact: Oncology". 2019 Journal Citation Reports. Clarivate. 2020.
{{cite book}}: CS1 maint: postscript (link)